Claims:

1. An anti-FcRn antibody or binding fragment thereof comprising (i) a heavy chain or heavy chain fragment having a variable region, wherein said variable region comprises three CDRs, wherein CDR H1 has the sequence given in SEQ ID NO: 1, CDR H2 has the sequence given in SEQ ID NO: 2, and CDR H3 has the sequence given in SEQ ID NO: 3 and (ii) a light chain or fragment thereof having a variable region comprising three CDRs, wherein CDR L1 has the sequence given in SEQ ID NO: 4, CDR L2 has the sequence given in SEQ ID NO: 5 or SEQ ID NO: 7 and CDR L3 has the sequence given in SEQ ID NO: 6.
2. An anti-FcRn antibody or binding fragment thereof according to claim 1 having a heavy chain comprising the sequence given in SEQ ID NO:12 and a light chain comprising the sequence given in SEQ ID NO: 8.
3. An anti-FcRn antibody or binding fragment thereof according to claim 1, wherein the antibody is humanized.
4. An anti-FcRn antibody or binding fragment thereof according to claim 1 having a heavy chain comprising the sequence given in SEQ ID NO: 25 and a light chain comprising the sequence given in SEQ ID NO: 16.
5. An anti-FcRn antibody or binding fragment thereof according to claim 1 having a heavy chain comprising the sequence given in SEQ ID NO: 59 and a light chain comprising the sequence given in SEQ ID NO: 51.
6. An anti-FcRn antibody or binding fragment thereof which binds human FcRn comprising a heavy chain, wherein the variable domain of the heavy chain comprises a sequence having at least 90% identity to the sequence given in SEQ ID NO: 25 and wherein the variable domain of the light chain comprises a sequence having at least 90% identity to the sequence given in SEQ ID NO: 16 and wherein the antibody molecule has the sequence given in SEQ ID NO: 1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2, the sequence given in SEQ ID NO: 3 for CDR-H3, the sequence given in SEQ ID NO: 4 for CDR-L1, the sequence given in SEQ ID NO: 5 or SEQ ID NO: 7 for CDR-L2 and the sequence given in SEQ ID NO: 6 for CDR-L3.
7. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to 6, wherein the antibody or binding fragment is a scFv, Fv, Fab or Fab' fragment.
8. An anti-FcRn antibody Fab' fragment according to claim 7 having a heavy chain comprising the sequence given in SEQ ID NO: 33 and a light chain comprising the sequence given in SEQ ID NO: 20.

9. An anti-FcRn antibody Fab' fragment according to claim 4 having a heavy chain comprising the sequence given in SEQ ID NO: 63 and a light chain comprising the sequence given in SEQ ID NO: 55.
10. An anti-FcRn antibody Fab fragment according to claim 7 having a heavy chain comprising the sequence given in SEQ ID NO: 29 and a light chain comprising the sequence given in SEQ ID NO: 20.
11. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to 10, wherein the antibody or binding fragment is conjugated to a polymer for example selected from starch, albumin and polyethylene glycol.
12. An anti-FcRn antibody or binding fragment thereof according to claim 11, wherein the polymer is PEG, for example with a molecular weight in the range 5 to 50kDa.
13. An anti-FcRn antibody according to any one of claims 1 to 6, wherein the antibody is a full length antibody.
14. An anti-FcRn antibody according to claim 13, wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P.
15. An anti-FcRn antibody according to claim 4, claim 13 or claim 14 having a heavy chain comprising the sequence given in SEQ ID NO: 37, SEQ ID NO:39 or SEQ ID NO:73 and a light chain comprising the sequence given in SEQ ID NO: 20.
16. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to 6 wherein the antibody or binding fragment thereof is a Fab-dsFv having a heavy chain comprising the sequence given in SEQ ID NO: 42 and a light chain comprising the sequence given in SEQ ID NO: 40.
17. A humanised anti-FcRn antibody or binding fragment thereof which binds an epitope of human FcRn which comprises one, two, three, or four amino acids selected from the group consisting of residues E115, W131, P132, and E133 and one or more residues selected from the group consisting of A81, G83, G84, K85, G86, P87, N113, L135, A136, and Q139 of human FcRn extracellular domain (SEQ ID NO: 48).
18. An anti-FcRn antibody or binding fragment thereof according to claim 17 which further binds one or more residues selected from the group consisting of L82, Y88, L112 and D130.
19. An anti-FcRn antibody or binding fragment thereof according to claim17 or 18, which has a binding affinity for human FcRn of 150pM or less at both pH 6 and at pH 7.4.
20. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to 19, which blocks binding of human IgG to human FcRn.
21. An anti-FcRn antibody or binding fragment thereof according to any one of claims 1 to 20 which does not bind human β2 microglobulin (SEQ ID NO:72).

22. An isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody according to any one of claims 1 to 21.
23. A cloning or expression vector comprising one or more DNA sequences according to claim 22.
24. A vector according to claim 23 wherein the vector comprises (i) the sequence given in SEQ ID NO: 30, 32, 34 or 36 and the sequence given in SEQ ID NO: 21 or 24 or (ii) the sequence given in SEQ ID NO: 38 and the sequence given in SEQ ID NO: 22, or (iii) the sequence given in SEQ ID NO: 74 and the sequence given in SEQ ID NO: 22 or (iv) the sequence given in SEQ ID NO: 41 and the sequence given in SEQ ID NO: 43.
25. A host cell comprising one or more cloning or expression vectors according to claim 23 or claim 24.
26. A process for the production of an antibody having binding specificity for human FcRn, comprising culturing the host cell of claim 25 and isolating the antibody.
27. A pharmaceutical composition comprising an anti-FcRn antibody or binding fragment thereof as defined in any one of claims 1 to 21 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.
28. A pharmaceutical composition according to claim 27 comprising other active ingredients.
29. An antibody or binding fragment thereof as defined one in any one of claims 1 to 21 or a composition as defined in claim 27 or 28 for use in therapy.
30. An antibody or binding fragment thereof as defined in any one of claims 1 to 21 or a composition as defined in claim 27 or 28, for use in the treatment of an autoimmune disease, such as myasthenia gravis, Pemphigus vulgaris, Neuromyelitis optica, Guillain-Barré syndrome, lupus, idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura.
31. Use of an antibody or binding fragment thereof as defined in any one of claim 1 to 21 or a composition as defined in claim 27 or claim 28 in the manufacture of a medicament for the treatment of an autoimmune disease, such as myasthenia gravis, Pemphigus vulgaris, Neuromyelitis optica, Guillain-Barré syndrome, lupus, idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura.